Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer

Neoplasia

Volumn 10, Issue 11, 2008, Pages 1253-1258

  Gorringe, Kylie L ^a   Choong, David Y H ^a   Williams, Louise H ^a,b   Ramakrishna, Manasa ^a,b   Sridhar, Anita ^a   Qiu, Wen ^a,b   Bearfoot, Jennifer L ^a,b   Campbell, Ian G ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BISULFITE; CHROMODOMAIN HELICASE DNA BINDING 5; K RAS PROTEIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BREAST CANCER; CHROMOSOME 1P; CHROMOSOME 1P36; CONFORMATION; EXON; FEMALE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; HEMIZYGOTE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; METHYLATION; MISSENSE MUTATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; SAMPLE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

EID: 55849092083     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08718     Document Type: Article

References (20)

1. Marfella CG and Imbalzano AN (2007). The Chd family of chromatin remodelers. Mutat Res 618, 30-40.
2. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, and Mills AA (2007). CHD5 is a tumor suppressor at human 1p36. Cell 128, 459-475.
3. White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory SG, Hogarty MD, Maris JM, et al. (2005). Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24, 2684-2694.
4. Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, Silverman KA, Xhao H, Mosse YP, White PS, and Brodeur GM (2008). Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 27, 803-810.
5. Thompson PM, Gotoh T, Kok M, White PS, and Brodeur GM (2003). CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 22, 1002-1011.
6. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274.
7. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, and Ingvarsson S (1999). Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 79, 1468-1474.
8. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, et al. (2005). High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7, 603-613.
9. Rozen S and Skaletsky H (2000). Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132, 365-386.
10. Foulkes WD, Englefield P, and Campbell IG (1994). Mutation analysis of RASK and the "FLR exon" of NF1 in sporadic ovarian carcinoma. Eur J Cancer 30A, 528-530.
11. Li LC and Dahiya R (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427-1431.
12. Williams LH, Choong D, Johnson SA, and Campbell IG (2006). Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res 12, 6967-6972.
13. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DY, and Campbell IG (2007). High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 13, 4731-4739.
14. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, et al. (2005). A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65, 6071-6079.
15. Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Ewing CM, Dalrymple S, Turner AR, Sun J, et al. (2008). Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 10, 897-907.
16. Sunyaev S, Ramensky V, Koch I, Lathe W III, Kondrashov AS, and Bork P (2001). Prediction of deleterious human alleles. Hum Mol Genet 10, 591-597.
17. Ng PC and Henikoff S (2001). Predicting deleterious amino acid substitutions. Genome Res 11, 863-874.
18. Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, and Orozco M (2005). PMUT: a Web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 21, 3176-3178.
19. Reed GH and Wittwer CT (2004). Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem 50, 1748-1754.
20. Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ, DeFazio A, Fox SB, Brenton JD, Bowtell DD, and Dobrovic A (2007). High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer 7, 168.